NASH / NAFLDPoster Morphometric Digital Pathology Analysis Reveals Differential Effects Of Lanifibranor And Semaglutide In The Biopsy-Confirmed Gan Dio-Nash Mouse Model
NASH / NAFLDPoster MORPHOMETRIC DIGITAL PATHOLOGY CONFIRMS CLINICAL TRANSLATABILITY FOR LANIFIBRANOR AND SEMAGLUTIDE IN BIOPSY-CONFIRMED GAN-DIO-NASH MICE
PosterNASH / NAFLD MORPHOQUANT-LIVER, AN AUTOMATED PATHOLOGIST-INDEPENDENT MORPHOMETRIC SOFTWARE, IDENTIFIED SIGNIFICANT DIFFERENCES BETWEEN STEATOTIC AND MASH LIVER BIOPSIES
PosterNASH / NAFLD Morphometric Analysis Of Sonic Hedgehog In Non-Alcoholic Fatty Liver And Steatohepatitis Patients By Morphoquant: A Potential Biomarker Of Disease Severity
NASH / NAFLDPoster Morphoquanttm The First Fully-Automated Morphometric Software For The Assessment Of Liver Biopsy, Reveals Significant Differences Between Non- Alcoholic Fatty Liver And Steatohepatitis Biopsies
NASH / NAFLD Selective Adipocyte Loss Of Angiopoietin-2 Prompts Female-Specific Obesity And Metabolic Syndrome
NASH / NAFLD Automated Whole Slide Image Analysis For A Translational Quantification Of Liver Fibrosis
NASH / NAFLD Best Practices in Liver Biopsy Histologic Assessment for Nonalcoholic Steatohepatitis Clinical Trials: Expert Opinion
Paris Nash 2021NASH / NAFLDPoster Distribution Of Lipid Vesicle Size As Potential Marker Of Nas Severity: Assessment With Morphoquant-Nash And Mri
Paris Nash 2021NASH / NAFLD Time-efficient and Reliable Automated Liver Fibrosis Quantification in Preclinical Fibrosis Models using WSI
